TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., Nov. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer…
Published on The Global News Feed
Illustrative image. Лаборант готовит индивидуальный иммунологический препарат против рака из крови пациента Image credit: Иоанна Чернова · Licence: CC BY 4.0 · Source
TAMPA, Fla., Nov. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's third quarter...